91亚色传媒

The editorial leadership team of the journal Molecular & Cellular Proteomics has chosen four investigators to present their current research duringat the 2022 91亚色传媒 Annual Meeting in Philadelphia.

Al Burlingame, MCP editor-in-chief, said, “This symposium will feature remarkable scientists who through their investigations have leveraged tools in immunology and molecular proteomics to uncover tumor antigens for the development of cancer vaccines.”

The session, titled “Exciting Biological Insights Revealed by Proteomics,” will be held at 3:15 p.m., Monday, April 4 in room 126A.

I will be chairing the session as well as giving a talk. I am a professor and principal investigator at the Institute for Research in Immunology and Cancer of Universit茅 de Montr茅al. My group employs mass spectrometry and proteogenomic approaches to identify tumor-specific antigens and to gain biological insights into their biogenesis.

I look forward to sharing the session with these three researchers:

Michal Bassani–Sternberg is an assistant professor at the department of oncology at the University of Lausanne. By leveraging high-sensitivity mass spectrometry, her group identifies clinically relevant cancer-specific major histocompatibility complex I ligands for personalized cancer immunotherapy.
Victor H. Engelhard is a professor of microbiology, immunology and cancer biology at the University of Virginia. His group made seminal contributions to the further understanding of immune responses to tumors and the identification of major histocompatibility complex–restricted tumor antigens.
Susan Klaeger is a research scientist in the proteomics platform at the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Her work focuses on the application of proteomics to translational research and on the development of methods to study antigen presentation and prediction algorithms for human leukocyte antigen binding.